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A B S T R A C T
Background: People who inject drugs (PWID) are at high risk of injection-related skin and soft tissue infections
(SSTI). If not treated promptly, these can lead to serious health complications, which are a considerable
healthcare burden. Data from two community surveys, with different approaches, were used to assess SSTI
prevalence and associated factors among PWID to inform intervention implementation.
Methods: Data were analysed from two surveys, a national surveillance survey (n=2,874; 2017–18) of infections
among PWID in the United Kingdom (UK) and an in-depth survey (n=455; 2018–19) of SSTI among PWID based
in London, UK. Multivariable logistic regression models were constructed to ascertain the factors associated with
self-reported SSTI.
Results: High prevalence of SSTI were reported in both samples: 52 % of participants from the national sur-
veillance survey reported having SSTI within the preceding 12 months and 65 % of the London sample reported
a lifetime history of SSTI. The factors associated with SSTI in both surveys were similar, including older age;
number of years injecting; number of attempts required to inject into the vein; injecting into the hands, feet,
groin or neck and re-using or sharing needles/syringes.
Conclusions: The number of PWID reporting SSTI in the UK is concerningly high. The two surveys used different
recruitment approaches but found similar associations. We provide strong evidence of a relationship between
venous access difficulty and SSTI. To stem the increase of SSTI and related complications in the UK, it is crucial
that interventions attend to the underlying causes of venous damage among PWID.
1. Introduction
People who inject drugs (PWID) constitute an extremely vulnerable
population with high levels of morbidity and premature mortality. Skin
and soft tissue infections (SSTI) disproportionally affect PWID with
global lifetime prevalence estimates ranging from 6% in Australia,
through 27% in the USA to 69% in Ireland (Larney et al., 2017;
Maloney, 2010; Salmon, 2009). They are also a common factor leading
to hospitalisation, for example, a study found SSTI accounted for 64%
of infections among PWID admitted to a hospital in Miami, USA
(Tookes et al., 2015). Despite the high global prevalence of SSTI, public
health policy and associated harm reduction interventions for PWID
have largely focused on preventing overdoses, and on the prevention
and treatment of blood borne viruses (Boucher et al., 2017), with
elimination targets in place for viral hepatitis and HIV (UNAIDS, 2017;
World Health Organisation, 2016). The development of associated
prevention and treatment interventions have been comparatively ne-
glected.
Bacterial SSTI in PWID have been increasing in the UK since 2012/
13, with yearly increases in hospital admission data reported, especially
in those aged 45–55 years old (18 % increase in admissions per year)
(Lewer et al., 2017). Laboratory surveillance of methicillin-sensitive
and methicillin-resistant Staphylococcus aureus (MSSA/MRSA) and
Group A streptococci (GAS), common bacteria found in SSTI, has also
shown a spike in infections (Public Health England, 2019a). Several
outbreaks of GAS and MRSA have been reported in England, with a
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large number of cases reported in prisons, among the street homeless
and/or PWID (Bundle et al., 2017; Kwiatkowska et al., 2018; Packer
et al., 2019; Public Health England, 2019a). The cause of the recent
increase in SSTI is not clear but is likely to be multifactorial, with
possible factors including an aging cohort of PWID, the impact of aus-
terity on services, increased homelessness, and changes in drug use
(Harris et al., 2020; Public Health England, 2019a)
Bacterial SSTI in PWID are most commonly found on the arms, legs,
buttocks or groin, corresponding to common drug injection sites (Hope
et al., 2008). SSTI are often characterised by the presence of pus
(specific to abscesses) or tenderness, swelling and redness (cellulitis). In
addition, poor vein health as a consequence of injecting drug use can
lead to chronic ulceration, particularly on the legs, which significantly
impact on PWID mobility and quality of life (Hope, 2010). PWID ex-
perience multiple barriers to care access, such as lack of material re-
sources, reluctance to disclose drug use, competing priorities and
stigma (Miller Lloyd et al., 2020; Neale et al., 2008), with many self-
treating their infections and/or delaying treatment seeking (Gilbert
et al., 2019; Roose, 2009). This can result in increased disease severity
and prolonged inpatient hospitalisation (Gilbert et al., 2019). Compli-
cations associated with chronic or severe SSTI include septic arthritis,
septicaemia, osteomyelitis, endocarditis and AA amyloidosis (del
Giudice, 2004; Harris et al., 2018). High levels of hospital admissions as
a result of SSTI complications place an unnecessary burden on health
care services; estimates of costs to the NHS are in the region of £77
million per annum (Marks et al., 2013).
Given the significant and increasing personal and healthcare burden
of injecting-related SSTI, there is urgent need to develop acceptable,
accessible and effective preventative interventions. Understanding the
factors associated with SSTI among PWID in the UK is crucial to inform
understanding of the rise in infections and implement effective inter-
ventions. Factors associated with SSTI are geographically variable,
given geographical differences in drug form, type, preparation and
administration practices (Ciccarone et al., 2016; Ciccarone and Harris,
2015; Public Health England, 2019b). Although previous studies have
examined the risks and associations with SSTI, using a range of time
frames and measures, none have compared data from surveys which,
when analysed together, provide both wide geographical coverage and
in-depth examination of SSTI. In this analysis we combine data from
two separate studies; one an in-depth survey exploring injecting prac-
tices and other factors associated with SSTI among PWID in London and
the other, a larger bio-behavioural surveillance study of infections and
harms among PWID across England, Wales and Northern Ireland. Our
analysis was undertaken primarily to assess the generalisability of the
in-depth survey findings to the wider population of PWID, but also to
explore the similarities and differences in the factors associated with
SSTI among PWID when their occurrence is measured over different
times frames (lifetime and recently) so as to improve our understanding
of the key associations. Considering the multiple recent outbreaks of
SSTI in PWID mentioned above, our integrated analysis of both datasets
is timely; facilitating an in-depth exploration of factors associated with
SSTI and their prevalence to inform implementation of population-
specific interventions.
2. Materials & methods
2.1. Study sample recruitment and eligibility
Anonymised data from two distinct surveys were used; 1) The
Unlinked Anonymous Monitoring (UAM) Survey of PWID and 2) The
Care and Prevent Study (‘Promoting skin and soft tissue infection care
and preventing AA amyloidosis renal failure among people who inject
drugs in the United Kingdom: a mixed-methods multi-phase study’).
Methodological details for both have been previously published (Harris
et al., 2018; Hope et al., 2014a; Public Health England, 2019c).
The UAM survey recruits PWID through a reflective sentinel sample
of specialist services for PWID, such as needle/syringe programmes or
addiction treatment centres (these services are widely provided
throughout the UK), throughout England, Wales and Northern Ireland.
Service users aged 18 and older, who have ever injected drugs, are
eligible to participate annually in this surveillance study and those who
agree to take part are offered an acknowledgement as well as a £4
voucher in compensation (£5 within London). Participants provide a
dried-blood spot sample, which is tested for antibodies against HIV,
hepatitis B and hepatitis C (HCV), and for HCV RNA, and self-complete
a short questionnaire which includes a single question on the symptoms
of an SSTI (a swelling containing pus (abscess), sore or open wound) at
an injecting site in the previous year. The UAM survey has approval
from Public Health England and the London Research Ethics Committee
(98/2/051). Analysis was limited to data from the 2017 and 2018
surveys for respondents who reported injecting during the past year and
who had answered questions on SSTI symptoms (n = 2,874). Those
who had not injected in the past year, and those who took part in 2018
who had already participated in the survey in 2017 were excluded (i.e.
duplicates were excluded by only including the first participation in the
two-year period, with repeats identified through reported year of last
participation).
Survey data from the Care and Prevent (C&P) Study, which re-
cruited participants from drug treatment centres, homeless hostels and
outreach services across London, were used. People were eligible to
participate in the survey if they had ever injected psychoactive drugs,
were aged 18 and over, and were assessed as able to provide informed
consent. Those who agreed to participate completed a detailed re-
searcher-administered, computer-assisted survey focused on SSTI and
provided a urine sample for proteinuria urinalysis. Ethical approvals
were obtained from the London Bridge Research Ethics Committee [17/
LO/0872] and the LSHTM Observational Research Ethics Committee
[12021]. Survey participants received a £10 voucher as reimbursement
for their time. In total, 455 PWID completed the survey between
October 2017 and March 2019. Participants were asked to identify if
they had ever had a SSTI and were provided with photographs of mild,
moderate and severe abscesses, cellulitis and leg ulcers to aid their
recall, ensure correct SSTI identification and provide a comparative
measure to assess SSTI severity. In addition, participants were asked to
self-report whether they had ever been diagnosed with HCV. Both
surveys collected similar or identical data on drug-use, injecting prac-
tices, sociodemographic characteristics and healthcare use. As the C&P
survey asked about lifetime prevalence of SSTI, data analysis was not
restricted to those who reported injecting in the previous year and in-
cluded the entire sample of PWID.
The possibility of someone participating in both studies is very low
due to very limited overlap in the locations used for recruitment re-
cruited. The majority (87 %) of UAM survey recruitment sites were
located outside of London, whereas all C&P recruitment sites were lo-
cated in London. Although both surveys recruited participants in
London, recruitment sites were focused in different areas and utilised
different services.
2.2. Analytical methods
Demographic and background characteristics of both samples were
compared using descriptive statistics. Both univariable and multi-
variable logistic regression models were used to investigate the crude
and adjusted associations of demographic variables and factors asso-
ciated with SSTI, respectively. We present estimates of odds ratios (OR),
95 % confidence intervals and tests of significance for each variable of
interest. Multivariable regression models were built using a manual
forward stepwise selection process to build separate models for each
dataset to identify the factors associated with reporting SSTI. As op-
posed to a single combined model, two separate models were built to
allow for flexibility and variability of different correlates in each da-
taset. Shortlisting for inclusion in the multivariable models was
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dependent on where there was evidence of an independent association
with the outcome (LRT p-value ≤0.05 in the UAM survey and ≤0.1 in
the C&P survey) and/or a suggested confounding effect from the
minimally adjusted models. Since a test for confounding does not exist,
an arbitrary ≥10 % difference in adjusted ORs was used as the defi-
nition of confounding in these analyses. All shortlisted variables were
iteratively inserted into the a priori model (which included age, and
gender). Following insertion, each variable’s impact on the crude OR of
all other factors already built into the model was assessed to identify
confounding. Likelihood Ratio Tests (LRTs) were also performed to
assess the variable’s contribution to the model as an independent risk
factor. At each forward step, retention in the model was dependent on
the factor having the largest confounding effect or strongest evidence of
being an independent risk factor. Assessment for multicollinearity in
both models was performed through the comparison of the standard
errors (SEs) of coefficients on the log scale to those of the unadjusted
models. Variables which showed an increase of> 10 % were further
investigated and individually removed to assess the nature of colli-
nearity. Provided there was no a priori reason for its inclusion, iden-
tified collinearity between pairs was controlled for by removing the
variables with the least confounding effect and the greatest change in
SE from the model.
3. Results
The characteristics of both samples were broadly similar. Both po-
pulations were skewed with respect to age, with 68 % and 57 % of
participants aged 35 years or more in the UAM survey and the C&P
survey, respectively, and more than two-thirds of participants identified
as male in both studies (71 % in UAM and 75 % in C&P). Homelessness
was common in both samples, with 78 % of the C&P study sample re-
porting a history of street homelessness and 50 % of participants from
the UAM survey reporting homelessness (both street and hostels) in the
past year. Testing of DBS samples collected in the UAM survey found 27
% had previously been infected with HCV (antibody positive and RNA
negative) and 29 % were currently infected with HCV (antibody and
RNA positive). Higher prevalence of HIV was found in UAM partici-
pants recruited in London (6.4 %) than in the overall sample (1.3 %). In
C&P, 54 % of participants self-reported a previous HCV diagnosis and
5.7 % reported a HIV diagnosis, corresponding to higher HIV pre-
valence in London found in UAM participants.
SSTI prevalence was high in both samples; 52 % of UAM partici-
pants reported having a SSTI symptom in the previous year and 65 % of
C&P participants reported an SSTI during their lifetime. In relation to
the photographs provided, 33 % of the C&P participants described their
worst SSTI as mild, 41 % as moderate and 26 % as severe. In both
studies, SSTI were least often reported in those who had been injecting
for less than one year (29 % and 28 % in UAM and C&P, respectively),
and they were most commonly reported among those who had made
four or more attempts (needle insertions) to achieve a successful in-
jection (66 % for UAM, 85 % for C&P).
Univariable analyses uncovered similar factors associated with SSTI
in both surveys. Participants who were aged 35+ years; had a current
or previous HCV infection; reported injecting for three or more years;
injected heroin or heroin and crack cocaine in combination; injected
into their hands, feet, neck, groin or other body sites other than their
arms or legs; and made more than one attempt at achieving an injection
(UAM: last injection, C&P: typical injection), had increased odds of
reporting SSTI (Tables 1 and 2).
Following adjustment for potential confounding, we found the fol-
lowing factors were associated with increased odds of reporting SSTI or
symptoms of SSTI in both samples: older age; injecting for three or more
years; injecting into the hands, feet, neck, groin or other body sites
other than their arms or legs; and making more than one attempt at
achieving an injection. Sharing of needle/syringes was associated in
UAM and reuse of needle/syringes in the C&P; these practices have
Table 1
Distribution of associated factors and Crude Odds Ratios for SSTIs: UAM
Survey, England, Wales and Northern Ireland, 2017–2018.
Variables of Interest N SSTIs in
past year
(%)
OR 95 % CI P-value
Total 2,874 1,486 (52) – – –
Demographics & General Health
Age
<25 89 32 (36) Ref. –
25−34 809 412 (51) 1.9 1.2−2.9 0.008
35+ 1,946 1,020 (52) 2.0 1.3−3.1
Gender
Male 2,046 1,018 (50) Ref. – 0.001
Female 818 461 (56) 1.3 1.1−1.5
Born in United Kingdom
Yes 2,667 1,379 (52) 1.2 0.8−1.6 0.38
No 172 83 (48) Ref. –
Hepatitis C Test Result
Negative (antibody negative) 1,182 551 (47) Ref. – <0.001
Current Infection (antibody
and RNA positive)
826 473 (57) 1.5 1.3−1.8
Past Infection (antibody
positive, RNA negative)
788 427 (54) 1.4 1.1−1.6
Not tested/insufficient sample 78 35 (45) 0.9 0.6−1.5
HIV Test Result
Negative 2,837 1,465 (52) Ref. – 0.64
Positive 36 20 (56) 1.2 0.6−2.3
Overdosed in past year
No 1,092 (49) Ref. – <0.001
Yes 531 319 (60) 1.6 1.3−1.9
Taken Part in Transactional Sex
Never 694 (47) Ref. – <0.001
Yes, but not in past year 150 84 (56) 1.4 1.0−2.0
Yes, in past year 147 101 (68) 2.5 1.7−3.6
Homeless (Street or Hostels)
No 584 280 (47) Ref. – 0.17
Yes, but not in past year 833 431 (52) 1.2 0.9−1.4
Yes, in past year 1,410 741 (53) 1.2 1.0−1.1
Ever Imprisoned
No 880 418 (48) Ref. – 0.01
Yes 1,929 1,017 (52) 1.2 1.1−1.5
Drug Injection and Preparation
Years injecting
<1 year 85 25 (29) Ref. – <0.001
1−3 years 188 80 (43) 1.8 1.0−3.1
3+ 2,506 1,316 (53) 2.7 1.7−4.3
Main drug Injected in past year
Opiates, Cocaine, Crack and
Combinations
1,980 1,053 (53) 2.0 1.3−3.0 <0.001
Amphetamine-like drugs 98 36 (37) Ref. –
Shared spoons for mixing in past month
No 1,581 791 (50) Ref. – <0.001
Yes 626 382 (61) 1.6 1.3−1.9
Shared filters in past month
No 1,624 814 (50) Ref. – <0.001
Yes 588 366 (62) 1.6 1.4−2.0
Injecting Frequency, Sites and Hygiene
Days injecting in past month
0−4 days 595 288 (48) Ref. – 0.053
5−9 days 291 161 (55) 1.3 1−1.8
10−20 days 359 190 (53) 1.2 0.9−1.6
20+ days 907 502 (55) 1.3 1.1−1.6
(continued on next page)
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been shown to be closely associated (Hope et al., 2014b) and these two
measures of equipment reuse both reflect constrained access to sterile
needles and syringes. Additional variables were also associated with
increased SSTI but were not common to both samples; i.e. having
overdosed in the past year; increased number of days injecting in the
past month; and receiving income through social welfare, or illicit ac-
tivities (Table 3). Two variables common to both were associated in one
survey but not the other. Main drug injected in past year was associated
with SSTI in the UAM, but not significant in C&P, probably due to the
lower power of the C&P study. The other was HCV status which was
associated in C&P but not the UAM. This is likely to relate to this
variable being measured differently, using self-reports of HCV diagnosis
in C&P and laboratory assessment in UAM. There was no evidence of
multicollinearity found during our analyses.
4. Discussion
Both samples found high prevalence of self-reported SSTI with
commonalities in associated factors that indicate that SSTIs are related
with venous access issues as well as hygiene. Lifetime prevalence esti-
mates of SSTI from the C&P study (65 %) were higher than those in
Australia (27 %) and Mexico (46 %) (Buchanan, 2006; Topp, 2008), but
similar to the levels reported in the USA (68 %) and Ireland (69 %)
(Biswanger, 2000; Maloney, 2010). UAM reported prevalence of SSTI in
the previous year (52 %) was higher than comparable studies, with 37
% the highest reported (to our knowledge) in a sample of 864 PWID
from the California, USA (Fink et al., 2013). Multivariable analyses il-
lustrate common associations with SSTI in both surveys: older age;
number of years injecting; injecting into the neck and/or groin; making
more than one attempt to achieve an injection. And markers of con-
strained needle and syringe supply (i.e. sharing or reuse).
The association with markers of constrained needle and syringe
supply, that is sharing in UAM Survey and reuse in C&P, highlights the
need to improve the provision of needle and syringe programmes
(NSPs) in the UK. New sterile injection equipment, and access to other
materials such as clean water and swabs, are key to maintain hygienic
injection practice, and so to reduce incidence of SSTI (Harris et al.,
2020). While NSPs are widely provided throughout the UK, their pro-
vision over the last decade has been impacted by austerity with this
increasingly focused on community pharmacies with fewer specialist
services (Britsh Medical Association, 2018; Local Government
Association, 2018). Our data indicates coverage is currently in-
sufficient, and there is also probably inequity in access (Public Health
Table 1 (continued)
Variables of Interest N SSTIs in
past year
(%)
OR 95 % CI P-value
Body Sites injected in past month
Arms or Legs only 783 367 (47) Ref. – < 0.001
Hands or Feet 447 247 (55) 1.4 1.1−1.8
Groin, Neck or Other 989 569 (58) 1.5 1.3−1.9
Typical Number of attempts to achieve last injection
1 1,157 438 (38) Ref. – < 0.001
2 623 341 (55) 2.0 1.6−2.4
3 395 255 (65) 3.0 2.4−3.8
4+ 623 408 (66) 3.1 2.5−3.8
Shared Syringes in past year
No 1,873 767 (41) Ref. – < 0.001
Yes 429 255 (59) 2.1 1.7−2.6
Abbreviations: N = number of individuals; OR = odds ratio; CI = confidence
interval; Ref = reference group.
Note: Those who reported injecting into their hands or feet could also have
injected into their arms or legs and those who reported injecting into their groin
or neck, could also have injected into their hands, feet, arms or legs.
Table 2
Distribution of associated factors and Crude Odds Ratios for SSTIs: Care and
Prevent Study, London, 2018–2019.
Variables of Interest N Ever
SSTIs (%)




Demographics & Sexual Health/Behaviour
Age
<25 58 26 (45) Ref. – <0.001
25−34 155 82 (60) 2.1 1.1−3.8 1.7-
35+ 242 188 (72) 3.1 5.6
Gender
Male 341 220 (65) Ref. – 0.68
Female 114 76 (67) 1.1 0.7−1.7
Ethnicity
White/White British 336 226 (67) 1.5 0.9−2.4 0.12
Black/Asian/Mixed/Other 89 52 (58) Ref. –
Diagnosed Hepatitis C
Yes 244 191 (78) 3.6 2.4−5.5 <0.001
No 211 105 (50) Ref. –
Diagnosed HIV





Yes 355 234 (66) 1.2 0.8−1.9 0.47




44 22 (50) Ref. – 0.03
Social Welfare/Illicit
Activities/Other
386 257 (67) 2.0 1.1−3.7
Drug Injection and Preparation
Years injecting
One year or less 57 16 (28) Ref. – <0.001
2−4 years 70 33 (47) 2.3 1.1−4.8
4+ years 328 247 (75) 7.8 4.2−14
Main Drugs Injected in past year
Opiates, Cocaine, Crack and
Combinations
266 184 (69) 2.5 0.9−6.8 0.07
Amphetamine-like drugs 17 8 (47) Ref. –
Ever Re-use Filters
No, Never/Yes, Occasionally 346 221 (64) Ref. – 0.01
Yes, Often 89 70 (79) 2.1 1.2−3.6
Main Dissolvent in past year
Citric Acid 237 162 (68) 1.0 0.5−2.0 0.98
Other 44 30 (68) Ref. –
Injecting Frequency, Sites and Hygiene
Typical Injecting Frequency
Once per week 57 25 (44) Ref. – <0.001
2–7 times per week 125 78 (62) 2.1 1.1−4.0
> once a day 273 193 (71) 3.1 1.7−5.5
Most common Body Site Injected in past year
Arms or Legs 88 17 (19) Ref. – <0.001
Hands or Feet 115 77 (67) 8.5 4.4−16
Neck, Groin or Other 252 202 (80) 16 9.1−31
Typical Number of attempts to achieve typical injection
1 202 101 (50) Ref. – <0.001
2 82 57 (70) 2.3 1.3−3.9
3 58 42 (72) 2.6 1.4−5.0
4+ 108 92 (85) 5.8 3.2−10
Typical injection-type
(continued on next page)
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England, 2019d); NSP provision urgently needs to be improved.
Age and length of time injecting are highly correlated with each
other (Dwyer et al., 2009; Fink et al., 2013; Hope et al., 2008;
Tempalski et al., 2013). The association of SSTI occurrence with age is
therefore likely to reflect the impact of long-term injecting and in
particular, the hardening/narrowing of veins (venous sclerosis), which
often occurs after injecting for many years (Maliphant and Scott, 2005).
Difficulty injecting into sclerotic veins can lead to unintentional sub-
cutaneous injection (or ‘missed hits’) (Rhodes et al., 2007) and require
an increased number of attempts to achieve an injection. Difficulty
accessing peripheral veins also precipitates transitions to more risky
injection sites, such as the femoral vein in the groin or the jugular vein
in the neck (Ciccarone and Harris, 2015; Darke et al., 2001). In both
samples, a high proportion of participants reported injecting into the
femoral or jugular vein in the past year (UAM: 45 %; C&P: 55 %) and
making four or more attempts before achieving an injection (UAM; 22
%, C&P: 24 %). As reported in previous studies, our analysis produced
strong multivariable associations between SSTI, multiple injection at-
tempts and injecting in the femoral or jugular vein (Harris and Rhodes,
2012; Hope et al., 2017). It is also possible that there is an element of
reverse causality at play, as transitioning to these other body sites and
higher numbers of missed injections may be a result of SSTI already
present in the arms or legs.
In both samples, and in accordance with the literature, women more
often reported an SSTI than men, however, due to limited power, the
association was not significant in the C&P sample and was thus not
listed as an association found in both surveys (Fink et al., 2013; Hope
et al., 2008; Lloyd-Smith et al., 2005; Spijkerman et al., 1996). In-
creased susceptibility to risk is likely due to an interplay of physical and
social factors. Women may experience loss of peripheral venous viabi-
lity earlier in their injecting trajectory than men, due to a finer venous
structure (Huxley, 2007). Difficult venous access, as previously stated,
can precipitate unintentional and intentional subcutaneous injection as
well as transitions to deeper veins, such as the jugular and femoral
veins, injection into which carries a greater infection risk (Lloyd-Smith,
2009; Topp, 2008). Women are particularly vulnerable to adverse
consequences of identification as a person who injects drugs (such as
loss of children, family support and/or sex-work income) and may
transition early to injecting into less visible sites such as the groin
(Harris and Rhodes, 2013). Gendered power dynamics can exacerbate
risk of unsafe injecting, with women more likely than men to have
limited control over drug purchase, injection equipment supply, drug
injection preparation or administration (Hope et al., 2010; Morris et al.,
2018). This can increase the likelihood of receiving injecting assistance
and using injecting equipment after others (Wood, 2003). Sex work is
Table 2 (continued)
Variables of Interest N Ever
SSTIs (%)
OR 95 % CI P-value
Venous 438 284 (64) Ref. – 0.62
Intramuscular/Subcutaneous 17 12 (71) 1.3 0.5−3.8
Typically Wash Hands Before Injecting
Never/Sometimes 321 213 (66) 1.2 0.8−1.8 0.37
Always 134 83 (62) Ref. –
Typically Wipe Skin with Alcohol before Injecting
Never/Sometimes 248 168 (67) 1.3 0.9−1.9 0.19
Always 207 128 (62) Ref. –
Ever Reuse Needles/Syringes
Always 149 40 (78) 4.1 2.0−8.6 < 0.001
Sometimes 255 186 (73) 3.0 2.0−4.7
Never 51 70 (47) Ref. –
Abbreviations: N = number of individuals; OR = odds ratio; CI = confidence
interval; Ref = reference group.
Table 3
Adjusted Odds Ratios of associated factors for SSTIs: Both Datasets.
Variables in
Multivariable Model
UAM Survey Care & Prevent Study
AOR (95 % CI) LRT AOR (95 % CI) LRT
Demographic & Health Variables
Age
<25 Ref. – <0.001 Ref. – 0.02
25−34 3.9 1.7−8.9 2.2 1.0−5.2
35+ 4.4 2.0−10.0 3.2 1.4−7.1
Gender 0.10
Male Ref. – 0.01 Ref. –
Female 1.4 1.1−1.7 1.4 0.8−2.6
Overdosed in past
year



















Drug Injection and Preparation Variables
Years injecting
<1 year Ref. – 0.004 Ref. – 0.10
1−3 years 2.0 0.8−4.8 1.5 0.6−3.7
3+ 3.0 1.4−6.5 2.2 1.0−4.9
Main Drug Injected
in past year





Injecting Frequency, Sites and Hygiene Variables
Main Injection Site
on Body in past
year
Arms or Legs Ref. – < 0.001 Ref. – <0.001
Hands or Feet 1.0 0.7−1.5 6.2 2.9−13





1 Ref. – <0.001 Ref. – 0.04
2 2.6 2.0−3.5 2.4 1.2−4.8
3 3.7 2.7−5.2 1.7 0.8−3.7
4+ 3.8 2.8−5.1 2.5 1.3−5.0
Days injecting in past month
0−5 days Ref. – 0.06 Φ
6−10 days 1.4 1.0−2.0
11−20 days 1.3 0.9−1.8
20+ days 1.5 1.1−2.0
Shared Needles/Syringes in past year
No Ref. – <0.001 Φ
Yes 1.7 1.3−2.3
Reuse Needles/Syringes
Never Φ Ref. – 0.03
Sometimes/Always 2.1 1.2−3.7
Φ Variable was not asked in the survey. ϖ Variable was asked but was not
significant in the final model. Abbreviations: N = number of individuals; AOR
= adjusted odds ratio; CI = confidence interval; LRT = likelihood ratio test p
value; Ref = reference group. Note: In the UAM study, questions based on
practices in the past month included a level with those who did not inject in the
past month in order to retain the full set of observations for multivariable
analysis.
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more likely to be a viable income-generation avenue for women who
inject drugs. Sex work among women is associated with more frequent
injecting, and therefore SSTI risk (Kerr et al., 2016). However, as sex
work may be undertaken to financially support high levels of injecting
(Morris et al., 2018) it is spurious to imply a causal link.
The majority of participants in both samples report injecting heroin
or a heroin/crack cocaine combination. Amphetamine or sole injection
of powder cocaine was relatively rare. Preparation of heroin and/or
crack cocaine for injection in the UK, requires use of an acidifier with
water to render these base drugs into an injectable solution. The C&P
study has previously shown that overuse of an acidifier for injection
was common, with 30 % using a whole sachet of acid or more (Harris
et al., 2019). There is a likely causal pathway between acidifier overuse
and venous damage, which in turn precipitates SSTI risk (Ciccarone and
Harris, 2015; Harris et al., 2019). Amphetamine-like drugs, with lim-
ited SSTI risk, are water-soluble and do not need to be prepared using
an acid (Ciccarone, 2011).
The substantial similarity of the associations with factors related to
venous damage in both samples, such as numerous repeat injection
attempts, reinforced the significance of these factors in influencing SSTI
development and the need for interventions addressing venous health
(Harris et al., 2019). High comparability of associations in both samples
strengthen their generalizability across the UK and so our confidence in
understanding the factors associated with SSTI that impact PWID.
The association between SSTI and repeat injection attempts –
something that may be easy for services to ask about – suggests a
possible avenue for identification of those with vascular access pro-
blems and/or poor injection technique for the offer of interventions.
Interventions offered should address, besides general injection hygiene,
the importance of vein health and include advice to improve this, e.g. to
reduce acid use, rotate injection sites, and recommendations to reduce
the number of injection attempts.
4.1. Limitations
Although the sample size of the UAM Survey was larger than C&P,
both were adequately powered. However, the smaller C&P study
sample and the differences in a number of the questions asked pre-
vented a combined analysis approach. Both data sources may be subject
to reporting bias as self- reports of SSTI symptoms were used, although
this was minimised in the C&P study, which used photos of typical
symptoms in the survey. However, previous studies have indicated that
self- reporting of SSTI is a reliable method to establish prevalence
(Morrison et al., 1997). As we used data from cross-sectional studies,
we were not able to investigate temporal relationships between factors
associated with and SSTI and indeed we could not eliminate the pos-
sibility of reverse causality. Systemic differences in questions asked
between surveys limited interpretation and thus require caution when
being compared. Finally, we cannot exclude the possibility of partici-
pant duplication between both studies, although, as addressed in the
methods, this is unlikely.
4.2. Conclusion
The results of this study highlight a high prevalence of SSTI amongst
PWID in the UK. Injecting- related SSTI are largely preventable, yet are
a significant burden, both in terms of the suffering experienced by
PWID and economic and health system costs. Together, our two data-
sets provide strong evidence of an association between difficulties with
venous access and SSTI occurrence and reiterate the importance of
providing easy access to the materials needed for hygienic injection. A
high proportion of respondents in both samples required multiple at-
tempts to achieve an injection and transitions to injecting in deep veins,
such as the femoral, were also common. There is a clear need to attend
to the underlying causes of venous damage among PWID in the UK. As
detailed elsewhere (Harris et al., 2019) overuse of acidifiers is a
potentially modifiable risk factor. Asking about repeat injection at-
tempts may be an easy to use approach for health services to identify
those with vascular access problems and/or poor injection technique
and so offer targeted interventions. Interventions should address, be-
sides general injection hygiene, the importance of vein health, in-
cluding advice on how to improve this.
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